chevron_leftBack
As of 24 April 2025, Hikma Pharmaceuticals PLC has a market cap of $5.57B USD, ranking #2626 globally and #94 in the United Kingdom. It ranks #228 in the Healthcare sector, and #35 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$5.57BUSD
4.2B GBP
Enterprise Value
$6.74BUSD
5.08B GBP
Revenue (TTM)
$3.31BUSD
2.5B GBP
EBITDA (TTM)
$834.04MUSD
628.63M GBP
Net Income (TTM)
$380.46MUSD
286.76M GBP
EBITDA Margin
25%
Profit Margin
11%
PE Ratio
14.8
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Riad Mishlawi
open_in_new
Employees
9,500
Founded
1978
Website
hikma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1.2% | 0.6% | -5.8% | -11% | -4.9% | 4.7% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
HIK
ISIN: GB00B0LCW083
Shares Out.:
Shares Outstanding:
221.886M1
Shares Float:
153.861M2
|
1.91K GBX | |
|
HKMPF
ISIN: GB00B0LCW083
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
26.20 USD | |
|
HKMPY
Hikma Pharmaceuticals PLC ADR
ISIN: US4312881091
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
51.25 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
